SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Nautilus’ management is scheduled to participate in a fireside chat on Monday, September 12th at 11:05 a.m. Eastern Time / 8:05 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Investor Contact
investorrelations@nautilus.bio
Media Contact
press@nautilus.bio
STUART, Fla., March 25, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform…
CONCORD, N.H., March 25, 2025 /PRNewswire/ -- Concord Orthopaedic ("COPA") is an orthopedic clinic located…
HAMPTON, Va., March 25, 2025 /PRNewswire/ -- Bioventra, the parent company and official manufacturer of Mitolyn,…
DOVER, Del., March 25, 2025 /PRNewswire/ -- The Mom's Choice Awards® has named Elora*, from leading…
New Sampling Technique Further Optimizes WATS3D Test Quality SUFFERN, N.Y., March 25, 2025 /PRNewswire/ -- CDx…
HOLLISTER, Calif., March 25, 2025 /PRNewswire/ -- Friday, the Appeals Court upheld the Bankruptcy Court's…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
